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Summary
There is mounting evidence that FceRII (CD23) and its soluble fragments (IgE-binding factors
[BFs] or soluble CD23) have pleiotropic activities . IgE-BFs are formed mainly by the proteolytic
cleavage of surface FceRII ; they are first released as 37- and 33-kD unstable molecules that are
subsequently transformed into 25-kD IgE-BFs. In this study, purified and radioiodinated 37-kD
IgE-BFs as well as 45-kD FceRII were used as substrates to identify the proteases leading to
the formation of 25-kD IgE-BFs. These substrates generate 25-kD IgE-BFswhen incubated with
several Fcc-RII-bearing cells, including CH01-7 cells (transfected with FceRIIcDNA) ; by contrast
FceRII - cells, including CHO control cells, have no effect . Highly purified unlabeled native
37-kD and recombinant 29-kD IgE-BFs also cleave labeled 45-kD FceRII into 25-kD IgE-BFs .
The proteolytic activity of these purified IgE-BFs is specifically removed by immunoprecipitation
with an antibody against IgE-BFs . These data strongly suggest that FceRII and some of its soluble
fragments play an active role in the proteolytic mechanism generating IgE-BFs. They are supported
by the observation that IgE-BFs released by CHOl-7 cells are cleaved exactly at the same sites
as B cell-derived IgE-BFs. Taken collectively, the results are compatible with an autoproteolytic
process .
T
he low affinity receptor for IgE (FceRII) is implicated
in protective immunity and in immunoregulation . The
FceRII on eosinophils, monocytes, and platelets is involved
in IgE antibody-dependent cellular cytotoxicity against para-
sites (1, 2) . On B lymphocytes, FceRII is identical to CD23
(3, 4), a B cell differentiation antigen selectively expressed
on sIgM/sIgD double-bearing lymphocytes . In a recent study
on mouseB cells, FceRII was shown to mediate IgE-dependent
presentation of antigen toT cells (5) . FceRII is a 45-kD gly-
coprotein containing oneWinked carbohydrate chain ofthe
complex type and several O-linked chains (5-9) . The cDNA
coding for the FceRII fromRPMI 8866 cells, a human lym-
phoblastoid B cell line, has been cloned (10-12) and used to
express IgE-binding molecules on the surface ofCHO cells
(11) . This receptor displays an unusual orientation with the
COOH terminus being extracellular and also displays a striking
homology to animal C-type lectins and to a new family of
adhesion proteins (13) .
The FceRII is cleaved into biologically active soluble frag-
ments, some of which retain the ability of binding to IgE,
i .e., IgE binding factors (IgE-BFs)l (14, 15) . Soluble FceRII
fragments were reported to have pleiotropic activities, in-
cluding (a) the regulation of the in vitro synthesis ofhuman
IgE (15-18), (b) the control of B and T cell proliferation
(19-22), (c) the induction in synergy with IIr1 of the differen-
tiation of early thymocytes (23), and (d) the inhibition of
monocyte migration (24) . IgE-BFs are mainly produced by
the cleavage of cell surface FceRII (25) . However, a small
fraction of the IgE-BFs may also be formed intracellularly
by proteolytic cleavage ofnewly synthetized FceRII (26) . IgE-
BFs exist in different molecular forms with apparent M, of
37,000, 33,000, and 25,000 (9, 27-30) . The NH2-terminal
sequences of these IgE-BFs were determined and matched
with the sequence deduced from the FceRIIcDNA in order
to localize their respective proteolytic cleavage site (28) . Re-
cently we reported that IgE-BFs are first produced as 37-kD
(and 33-kD) IgE-BFs which are then cleaved into 25-kD IgE-
'Abbreviation used in this paper. IgE-BFs, IgE binding factors .
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pressed on FceRII bearing cells but not on FceRII- cells and
it is inhibitedby iodoacetamide (28) . Thepresent studyshows
that FceRII itself, as well as some of its soluble fragments,
plays an active role in the formation of 25-kD IgE-BFs.
Materials and Methods
Reagents. Carrier-free Nat"I was obtained from Amersham
Corp. (Arlington Heights, IL); Affi-gel 10, SDS-PAGE standards
(10,000-100,000 molwt), Coomassie Brilliant Blue R-250, SDS,
acrylamide, N,N-methylene-bis-acrylamide, N,NX,N-tetramethyl-
ethylenediamine (TEMED), Tris, glycine, ammonium persulfate,
2-ME, and molecular weight markers for gel filtration were pur-
chased from Bio-Rad Laboratories (Richmond, CA); PMSF, ben-
zamidine hydrochloride, e-amino caproic acid, iodoacetamide, Hepes,
NP-40, andBSAwere obtained from SigmaChemical Co. (St. Louis,
MO). RPMI 1640 andHBSS were purchasedfrom Flow laborato-
ries (McLean, VA) . MEM, trypsin-EDTA, andFCSwere obtained
from Gibco Laboratories (Grand Island, NY); HB101 culture
medium was from Hana Biologics (Berkeley, CA) and lactoperox-
ydase was from Calbiochem-Behring Corp . (San Diego, CA).
Immobilon''-P transfer membraneswere purchasedfrom Millipore
Corp. (Bedford, MA).
Cell Culture.
￿
RPMI 8866 andRPMI 8226 cells were cultured
in RPMI 1640 medium supplemented with 5 MM . L-glutamine,
10% FCS, 50 IU penicillin, and50 mg/ml streptomycin . TheCHO
cells were maintained in MEM medium supplemented with 5%
FCS, penicillin-streptomycin, and L-glutamine.
Antibody and Immunoadsorbents. The mAb against FceRII
used in this study has been described : 207.25.A.4.4/30: IgGl, :
mAbER30 (31) . Affi-gel 10 was coupled tomAbER30 at 10 mg/ml,
according to Bio-Rad manual instructions .
Cell Surface Radioiodination and Membrane Solubilixation .
￿
The
RPMI 8866 cells were surface radioiodinated at room temperature,
using lactoperoxydase as described elsewhere (8) . Briefly, 3-4 x
10' cells were washed thrice with D-PBS (8 mM Na2HP04-7H2O ;
137 mM NaCl ; 1.5 mM KH2P04; 2.7 mM KCI, pH 7.3) and
resuspended in 0.5 ml ofthe same solution. To this cell suspension,
5 Al of a 3.614M Na1"I (3.68 nmol/mCi) carrier-free solution was
added.The reaction was startedby adding 12 IAl of lactoperoxidase
(166 U/ml) and 12 p,l of 9mM H201 . This reaction mixture was
gently shaken andincubated during 1 min . Two further additions
of lactoperoxidase (12 Al) and H102 (12 pl) were made at 1-min
intervals. The cells were then washed three times with 10 ml of
cold D-PBS and resuspended in HB101 serum-free medium at a
density of 106 cells/ml for culture or in 1.0 ml of cold lysis buffer
for membrane solubilization . The lysis buffer was made in D-PBS
containing 0.5% NP-40, 1 mM PMSF, 10mM benzamidine hy-
drochloride, 50 MM e-amino caproic acid, and 20mM iodoaceta-
mide. The insoluble material was removed by centrifugation at
10,000 g for 30 min at 4°C .
Purification of 1251-labeled FceRII.
￿
A total of 1 ml of cell lysate
from radioiodinated RPMI 8866 cells was mixed with 200 p .1 of
mAbER 30-Affi-gel; after overnight rotation at4°C, the gel was
washed with 30 ml of D-PBS containing 0.5% NP-40 and with
30 ml of D-PBS containing 200,ug/ml BSA. Bound material was
eluted with 0.2M glycine-HCI, pH 2.3, containing 200 ug/ml
BSA. The eluted material was neutralized with 2M Tris, pH 9.0,
and dialyzed against D-PBS .
Purification of '15I-labeled 37-hD IgE-BFs.
￿
Briefly, 3 x 10'
RPMI 8866 cells were surface radioiodinated as described before
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and cultured for 2 h (106 cells/ml) in HB101 medium in the pres-
ence ofiodoacetamide (10 mM). At theendof the incubation, the
culture supernatant wasrecovered and 1 M Tris-HCI, pH 7.3 ; 1%
NaN3 was added to a final concentration of 66 mM Tris-HCI,
0.06% NaN3 . This supernatant was subsequently filtered on a
Whatman filter paper No . 4 and adsorbed on 300 ji1 ofmAbER
30 Affigel at a flow rate of 2 ml/h . The gel was then washed and
the bound material was eluted as described for the purification of
1111-FceRII .
ElectrophoresisandAutoradiography .
￿
SDS-PAGE wasdone on 1.5-
mM 12.0% slab gels according to Laemmli (32) . Samples containing
5% (vol/vol)2-ME were boiled for2minand applied on gels. The
gels were stained with 0.25% (wt/vol) Coomassie Brilliant Blue,
destained, and dried. Autoradiography was performed at -70°C
by using XAIt5 x-ray film (Eastman Kodak Co ., Rochester, NY).
Purification of 29- and 37-kD IgE-BFs.
￿
For the purification of
37-kD IgE-BFs, the supernatant from RPMI 8866 cells cultured
for 4 h in serum-free HB101 medium at 2 x 106 cells/ml in the
presence of iodoacetamide (20 mM) was adsorbed on 1 ml of
mAbER 30-Affi-gel at a flow rate of 2 ml/h . The gel was then
washed with 50 ml ofD-PBS containing 0.05% NP-40and5mM
iodoacetamide . The bound material was eluted with 3.5 M
MgC12, pH 4.8, made 0.05% NP-40, and dialyzed against PBS
containing 0.05% NP-40andiodoacetamide (5mM). The dialyzed
material was further purified on 1 ml of freshly preparedmAbER
30-Affi-gel . This gel was washed witli D-PBS containing 0.05%
NP-40 and the 37-kD IgE-BFs were eluted with 3.5 M MgC11,
pH 4.8, made0.05% NF-40 . The eluted material was subsequently
dialyzed againstD-PBS containing0.05% N-P40andconcentrated
by centrifugation at 6,000g on an IEC refrigerated centrifuge using
Centricon 10 microconcentrators (Amicon Corp., Danvers, MA) .
This procedurewas also used to isolate29-kD and 25-kD IgE-BFs
from the supernatant ofCHO-29 andCHO 20.3 cells, respectively,
with the exception that iodoacetamide was omitted in every step.
In some experiments, the affinity-purified 29-kD IgE-BFs were fur-
ther purified by HPLC ion-exchange chromatography exactly as
previously described (27) .
Fractionation ofIgE-BFs by GelFiltration onHPLC.
￿
25 pl of con-
centrated culture supernatants were applied on aBIOSILTSK250
column (Bio-Rad) and eluted with a buffer containing 0.05M
Na2SO4 and 0.02M NaH2P04, pH 6.8, at a flow rate of 0.5
ml/min.Thecolumn was calibrated by using theBio-Rad gel filtra-
tion standards . Fractions (0.25 ml)were tested byRIA for IgE-BFs
as described elsewhere (14) . The results are expressed in units/milli-
literby reference to a standard preparation . 1U of IgE-BFs corre-
sponds to 150 pg of 25-kD IgE-BFs .
IgE-BFsAmino Acid Sequence Analysis.
￿
IgE-BFs were isolated
from the culture supernatant ofCH01-7 cellsby affinity chroma-
tography and fractionated by PAGE in the presence of SDS as de-
scribed. The gel was then electroeluted to Immobilon"`P transfer
membrane according to the Millipore tech protocol TP006 and
TP017 . Briefly, the gels were soaked in transfer buffer (25mM Tris,
192mM glycine, 15% methanol [vol/voll, pH 8.3) for 30 minand
the Immobilon membrane was pre-wet in 100% methanol and
soaked in transfer buffer for30 min . The gelwas sandwiched be-
tween theImmobilonmembrane and sheets of filter paper, assem-
bled into a Bio-Rad transblot cell apparatus and electroeluted for
5 h at 50 V in transfer buffer. The membrane was stained with
0.2% Coomassie brilliantblue R-250 in45% methanol, 10% acetic
acid, anddestained in90%methanol, 7% acetic acid . The stained
bandswere excised from themembrane andloaded into a sequencer
cupofagas-phase sequencer (No.470A ; Applied Biosystems, Inc.,
Foster City, CA) . The phenylthiohydantoin derivatives ofthe aminoacids obtained by Edman degradation were identified by reverse-
phase HPLC using an Altex 5 Am ultrasphere-ODS column (33) .
Expression of FceRII, 37-, 29-, and 25-kD IgE-BFs in CHO
Cells. The construction of the expression plasmidpSVd-ER, and
the selection of cell lineCHO (1-7) expressing humanFceRII have
been described (11) . In order to express 37-, 29-, and 25-kD IgE-
BFs, plasmid pSVd-ER was modified. First, a 2.3-kb Dhfr selec-
tion marker, derived from plasmid pSVneo2911 (34) by digestion
with Sall and XhoI, was integrated into the Sall site of pSVd-ER
next to the ampicillin gene. Second, theSV40 enhancer/promoter
of pSVd-ER was replaced by the 540-bp Accl-HindIII fragment
of the SV40-MCMV virus Pl (35) . Third, direct secretion of37-,
29-, and25-kDIgE-BFs was achieved by removal ofthe leader and
NH2-terminal coding sequences of FceRII cDNA up to amino
acid residues 75, 118, and 147, respectively, andsubsequent replace-
ment by an artificialDNA segment coding for the signal sequence
of the avian influenza virus hemagglutinin (36) . These modifica-
tions yielded the following plasmids: pCAL12Mdhfr, pCAI,8Mdhfr
and pCAIrIOMdhfr, which were used to transfect Dhfr - CHO
DUKX-BI cells . After 14dofDhfr selection, single colonies were
picked and expanded, and colonies that produce 37-kD IgE-BFs
(CHO-37),29-kDIgE-BF (CHO-29), and 25-kD IgE-BFs(CHO-
20.3) at high level were selected. These cell lines were maintained
inMEMmedium lacking ribonucleosides and deoxyribonucleosides .
Cleavage of '251-labeled45-kDFceRII by Purified Recombinant 29-
kD IgE-BFs. In typical experiments 60 pmol ofrecombinant 29-
kDa IgE-BFs (in50 Al D-PBS, 0.05% NP40) was incubated with
50 Al (5,000 cpm) of radioiodinated 45-kD FceRII dissolved in
D-PBS in a final volume of 100 F .1 . After 17-24 h of incubation
at 37°C, sampleswere taken into 80 A1 of SDS-PAGE electropho-
resis buffer consisting of63 nM Tris-HCl, pH 6.8 ; 2% SDS ; 10%
glycerol; 5% 2-ME, andwere boiled for2 min . In controlsamples
the 1151-labeled 45-kD FceRII was incubated with D-PBS con-
taining0.05% NP-40. SDS-PAGE wasthen performed in 12%poly-
acrylamide gels at 10 mA during 17 h .
Results
Purified 125 1-labeled FceRII Is Cleaved into 2541) IgE-BFs
after Interaction with FceRII-bearing Cells. In the course of
our studies on the degradation of37-kD IgE-BFs into 25-
kD IgE-BFs we noticed that affinity-purified and radiolabeled
45-kD FceRII was degraded into 25-kD IgE-BFs when in-
cubated with FceRI' cells (RPMI 8866, HC-EBV trans-
formed cell lines, U937 macrophage cell line), whereas the
same preparation remained stable when incubated with
FceRII - cells (RPMI 8226, U266 myeloma cells) . One such
experiment is shown in Fig. 1 a where 1251-labeled 45-kD
FceRII was incubated with an NP-40 lysate of either
FceRII+ (RPMI 8866 cells) or FceRII - cells (RPMI 8226).
As seen, the45-kD labeled FceRII was cleaved into a25-kD
molecule only by the NP-40 lysate of RPMI 8866 cells .
To further examine whether the ability of a given cell line
to cleave 1251-labeled FceRII into IgE-BFs is related to the
expression of surface FceRII, we compared CH01-7 cells
(transfected with FceRII cDNA) with CHO control cells .
As seen, theCH01-7 cell line cleavesboth the 45-kD FceRII
(Fig . 1 b) and the 37- and 33-kD IgE-BFs (Fig. 1 c) into 25-
kD IgE-BFs whileCHO control cells have no effect . These
experiments indicate that theexpression ofFceRII is required
for a given cell line to cleave 1251-FceRII . This may be ex-
Figure 1 .
￿
(a) Cleavage of
FceRII by RPMI 8866 cells NP-40
extract. SDS-PAGE analysis and
autoradiography of 1251-labeled
FceRII incubated with PBS (lane
A), NP-40 cell lysates from RPMI
8226 (lane B) and 8866 cells (lane
C) . 50 p,l of 1251-labeled FceRII
(5,000 cpm; about 6 pmol) were
incubated for 24 h at 37°C with
either 50 Al of PBS or 50 /1 of
NP-40 cell lysates. The cell lysates
were prepared as described in
Materials and Methods with the
exception that protease inhibitors
were omitted . The lysate of RPMI
8866 cells contained 50 nM of
FceRII as estimated by RIA . The
molecular weight markers are indi-
cated at the side .
Cleavage of FceRII (b) and 37-
kDa IgE-Brs (c) by CH01-7 cells.
1251-labeled FceRII (b) and 1251-
labeled 37-kD IgE-BFs (c) were in-
cubated with HB101 culture
medium (lanes A), CHOI-7 cells
(lanes B) andCHO control cells
(lanes C) . CHO cells were cul-
tured in 96-well plates until confluence was reached. The culture supernatants were then removed from the wells and replaced with 50 Fal of
HB101 medium and 50 A1 of either 1251-labeled FceRII or 12SI-labeled 37-kD IgE-BFs (5,000 cpm; about 6 pmol) . After a 24-h incubation at
37°C, the supernatants were analyzed by SDS-PAGE and autoradiography.
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FceRII or by the FceRII-dependent activation ofanunknown
protease . The latter should be ubiquitous since it is expressed
on several human as well as hamster cells.
Moreover, several serine protease or thiolesterase (SH-
protease) inhibitors failed to inhibit this cell-associated pro-
teolytic activity. Indeed, with the exception ofiodoacetamide,
none of the following inhibitors could inhibit the formation
of 25-kD IgE-BFs byRPMI 8866 cells : e-amino caproic acid
50mM, benzamidine hydrochloride (10 mM), PMSF (1 mM),
leupeptin (100 Ag/ml), cystatin (10 Ag/ml), soybean trypsin
inhibitor (100 Ag/ml), pepstatin (10 jAg/ml),TLCK (4mM),
TPCK (4 mM), HgC12 (10 LM), 2-ME (1 mM), and EDTA
(10 mM) . In these experiments, RPMI 8866 cells were in-
cubated for 2 h in the presence of the protease inhibitors .
The IgE-BFs in the culture supernatants were measuredby
RIA and their molecular weight was determined by HPLC
gel filtration . In keeping with our previous studies, cells cul-
tured in the presence of iodoacetamide released a 37-kD in-
stead of 25-kD IgE-BFs.
The Proteolytic Activity Is Associated with the 37-kD IgE-
BFs. To further analyze the cleavage of37-kD IgE-BFs into
25-kD IgE-BFs by FceRII-bearing cells, a functional recom-
binant 37-kD IgE-BFs was expressed inCHO cells after stable
transformation with a mammalian expression vector containing
the coding region of FceRII corresponding to amino acids
77-321 . Surprisingly, the 24-h culture supernatant of these
transformed CHO cells (CHO-37) contained a 25-kD IgE-
BFs and not a 37AD IgE-BFs as expected. The latter was
detected onlywhen CHO-37 cells were cultured in the pres-
ence of iodoacetamide . The instability of 37-kD IgE-BFs sug-
gested that these may be endowed with the proteolytic ac-
tivity ascribed to the intact FceRII . In the next series of
experiments we examined the ability of several native or recom-
binant IgE-BFs to cleave 1251-labeled 45-kD FceRII . Fig . 2
shows that both purified native 37-kD IgE-BFs as well as
a recombinant 29-kD IgE-BFs are capable of cleaving the la-
beled receptor into25-kD IgE-BFs. The 29-kD IgE-BFs were
purified from the supernatant ofCHO cells transfected with
acDNA coding for the amino acids 120-321 of the FceRII .
Contrary to the recombinant 37-kD IgE-BFs, the 29-kD IgE-
BFs are rather stable in the absence of iodoacetamide . In sev-
eral similar experiments, we could hardly detect any proteo-
lytic activity of either native or recombinant 25-kD IgE-BFs .
The possibility that the proteolytic activity associated with
the purified IgE-BFs might be due to a contaminating pro-
tease was not supported by the following experiments. First,
immunoprecipitation of the 37-kD IgE-BFs by anti-FceRII
mAb completely abrogates the proteolytic activity (Fig. 2
c) . Second, 25-kD and 37-kD IgE-BFs were purified from
parallel culture supernatants of RPMI 8866 cells by using
identical purification procedure . The only difference was that
RPMI 8866 cells were supplemented with iodoacetamide for
the preparation of37-kD IgE-BFs. When reacted with radio-
iodinated 45-kD FceRII, only the 37-kD IgE-BFs have pro-
teolytic activity (data not shown) .
Iodination Procedure o,f FceRII Destroys the Proteolytic Ac-
tivity The above experiments were made possible because,
in contrast to the unlabeled molecules, radiolabeled 45-kD
FceRII or 37-kD IgE-BFs are stablewhen incubated for 24 h
at 37°C . Since the labeled molecules may still be cleaved,
it may be predicted that the iodination procedure destroys
the proteolytic activity. To examine this possibility, purified
37-kD IgE-BFs were iodinated with cold iodine (0.1 mM)
Figure 2 .
￿
(a) Cleavage of FceRII by
purified 37-kD and 29-kD IgE-BFs.
50 F1 of 1251-labeled FceRII (5,000
cpm; about 6 pmol) were incubated
for 24 h at 37°C with 50 ILI of PBS
(lane A), 50 jut of affinity chromatog-
raphy purified 37-kD IgE-BFs (0 .3
nmol) (lane B), and 50 ul of recom-
binant 29-kD IgE-BFs (0 .3 nmol)
purified by affinity chromatography
followed by HPI.C ion-exchange chro-
matography (lane C) . The mixtures
were analyzed by SDS-PAGE and au-
toradiography. SDS-PAGE molecular
weight markers are indicated at the
side. (b) SDS-PAGE analysis of the
IgE-BFs (29-kD) purified from the
culture supernatant of CHO-29 cells
(lane A) . Lane B is an empty well .
The gel was stained with silver ni-
trate. (c) 1251-labeled FceRII were in-
cubated with PBS (lane A), superna-
tants from 37-kD IgE-BF preparation
immunoprecipitated with anti-FceRII mAb (lane B), or antiprolactin mAb (unrelated mAb of the same IgG subclass) (Lane C) . A preparation of
37-kD IgE-BFs (0 .3 nmol in 100 F1) was supplemented with 2 Wg of mAbER 30 or antiprolactin mAb. After a 4-h incubation at 4°C, the
mixtures were precipitated with 30 ug of affinity-purified rabbit anti-mouse IgG. The supernatants (50 JAI) were incubated for 24 h at 37°C
with 50 Al of 1251-labeled FceRII (5,000 cpm; N6 pmol) .
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￿
Effect of iodination pro-
cedure on the cleavage of FceRII . 50
,ul of 1251-labeled FceRll (5,000 cpm;
N6 pmol) were incubated for 24 h at
37°C with 50 A1 of PBS (lane A), 50
pl of iodinated 37-kDa IgE-BFs (0 .3
nmol) (lane B) and 50 ul of 37-kDa
IgE-BFs (0.3 nmol) (lane C) . The "'
mixtures were analyzed by SDS=PAGE
and autoradiography. SDS-PAGE mo-
lecular weight markers are indicated at
the side.
by using the same lactoperoxidase method as for cell surface
radioiodination and their proteolytic activity was compared
to that of control 37-kDa IgE-BFs preparations treated ex-
actly the same way except that lactoperoxidase was omitted
(Fig . 3) . The results show that iodinated 37-kD IgE-BFs were
unable to cleave the 1251-labeled FceRII while 37-kD IgE-
BFs cleaved 1251-FceRII into 25-kD IgE-BFs . The inactiva-
tion of the proteolytic activity associated with the 37-kD
IgE-BFs by the iodination procedure is caused by 12ctoperox-
idase oxidation rather than by the iodination of the mole-
cules. Indeed, treatment of37-kD IgE-BFs with lactoperox-
idase alone abrogates the proteolytic activity (data not shown) .
Similar observations were also made with intact RPMI 8866
cells iodinated with cold iodine and incubated with 1251_
FceRII in the presence of cycloheximide to inhibit the syn-
thesis of new receptor molecules (data not shown) .
CHO Cells Expressing FceRII Produce IgE-BFs Identical to
Those Releasedfrom RPM18866 Cells.
￿
Our interpretation
Figure 4 .
￿
SDS-PAGE analysis
of the affinity chromatography-
purified radiolabeled FceRII
from RPMI 8866 (lanes A and
B) and CH01-7 (lanes C and
D) cells . (Lanes A and C)
KSCN eluates ; (lanes B and D)
glycine eluates . Similar amount
of radioactivity was applied to
each lane . SDS-PAGE molec-
ular weight markers are indi-
cated at the side.
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￿
Fractionation by gel filtration of the supernatant from
CH01-7 cells cultured for 6 h in HB101 medium in the presence
(0) or absence of 20 mM iodoacetamide (0) . The supernatants were
concentrated 50-fold and fractionated by HPLC on a TSK 250
column.
ofthe above results is that the cleavage ofFceRII and its soluble
37-kD IgE-BFs into 25-kD IgE-BFs is mediated by either
an autoproteolytic mechanism or by an FceRII-dependent
ubiquitous protease. If this view is correct itmay be predicted
thatCHO cells expressing recombinant 45-kD surface FceRII
should release IgE-BFs that are identical to those of B cell
origin . In the next series of experiments we first ascertained
that recombinant FcjERII onCHO cells has the same struc-
ture as on B cells (Fig. 4) . We then analyzed the IgE-BFs
released by CHOI-7 cells . These IgE-BFs were purified by
affinity chromatography, fractionated by SDS-PAGE, and then
transferred to immobilon-P transfer membrane by electro-
phoretic blotting. The NHrterminal sequence of the first four
residues was determined on the excised 25-kD stained band
as described . A double sequence was obtained corresponding
to leu-Arg-Met-Glu and Met-Glu-Leu-Gln . Matching these
sequences with those deduced from the FceRII cDNA indi-
cates that the 25-kD IgE-BFs from CHOl-7 cells starts with
leucine at position 148 or methionine at position 150 of the
FceRII, which are exactly the same two proteolytic cleavage
sites as for the 25-kD IgE-BFs isolated from RPMI 8866 cells
culture supernatant (10-12) . Moreover, in additional experi-
ments, we observed that as in the case of RPMI 8866 cells,
the 25-kD IgE-BFs are derived from soluble 37-kD IgE-BF
precursors . Indeed, when CH01-7 cells are cultured in the
presence of iodoacetamide, the molecular mass of IgE-BFsis shifted from 25 to 37-kD as determined by HPLC gel filtra-
tion (Fig. 5).
Discussion
IgE-BFs are mainly produced by the proteolytic cleavage
of surface FceRII (9, 25). The rate of this process is reduced
by IgE, whereas it is increased by treatment ofFceRII-bearing
cells with tunicamycin, indicating that the Winked carbo-
hydrate chain stabilizes the receptor (25). We recently reported
that IgE-BFs are first released as 33-37-kD molecules which
are subsequently transformed into 25-kD IgE-BFs (17). The
latter are much more stable and they are detected in the su-
pernatants of 2-3 wk cultures in human sera and even in
urine (37) .
In the course ofour initial studies on the cloning of FceRII
cDNA, we noticed that after purification to homogeneity,
45-kD FceRII molecules were unstable and degraded into
37-, 33-, 29-, and 25-kD fragments. In contrast, most prepa-
rations of radiolabeled receptors isolated from surface radio-
iodinated cells were rather stable (in the absence of inhibi-
tors), even when incubated for 24 h or more at 37°C. Such
preparations were therefore used as a substrate for the iden-
tification of the proteolytic enzymes that cleave FceRII. In
this study, we first observed that the ability of a given cell
line to cleave 1251-labeld 45-kD FceRII or 37-kD IgE-BFs is
dependent upon the expression of FceRII. Indeed, 1251_
labeled 45-kD FceRII and its 37-kD fragments are transformed
into 25-kD IgE-BFs when incubated with several FCeRII-
bearing cells (including the transfected CH01-7 cells), while
the same preparations remain stable when incubated with sev-
eral FceRII - cells (including CHO control). There are two
possible explanations for these observations: (a) FceRII is
degraded by a receptor-associated proteolytic mechanism
(where one FceRII molecule could cleave adjacent identical
molecules), or (b) it is degraded by a protease that is both
ubiquitous and activated by FceRII: These two possibilities
are also supported by the observation that CH01-7 cells, ex-
pressing functional recombinant IgE receptor, release IgE-
BFs identical to those released by B cells (i.e., they have the
same molecular weight and the same NH2-terminal end
cleavage sites). To examine these alternatives it was necessary
to test the ability ofpurified unlabeled FceRII to cleave radio-
iodinated FceRII. Because it is difficult to obtain convinc-
ingly pure preparations of 45-kD FceRII, the proteolytic ac-
tivity of soluble IgE-BFs was examined. The instability of
37-kD IgE-BFs suggested that it might be endowed with
such activity. Indeed, highly purified 37-kD IgE-BFs proved
to be capable ofcleaving radiolabeled 45-kD FceRII, as well
as radiolabeled 37-kD IgE-BFs, into 25AD IgE-BFs. Moreover,
recombinant and stable 29-kD IgE-BFs but not native or
recombinant 25AD IgE-BFs displayed the same activity. Three
observations militate against the possibility that the proteo-
lytic activity of the purified 37- and 29AD molecules was
due to a co-purified protease. First, the 24-h culture superna-
tant of FceRII-bearing B cells (containing 25-kD IgE-BFs)
has no activity (28). Second, immunoprecipitation ofthe 37-
kD IgE-BFs specifically removed the proteolytic activity of
the preparation. Third, when 37 and 25 kD were isolated
from the culture supernatants ofthe same cell line using iden-
tical purification procedures, only the 37-kD molecules were
capable of cleaving the labeled 45-kD FceRII. Taken collec-
tively, the present data suggest, but do not demonstrate, that
IgE-BFs are produced by an autoproteolysic mechanism. This
possibility is currently examined more directly by (a) using
synthetic peptides as substrate, and (b) comparing the pro-
teolytic activity of several FceRII mutants, aiming to localize
the putative active site(s).
Autoproteolysis was recently described as a mechanism to
activate or inactivate an increasing number of biologically
active proteins in bacteria (38, 39), virus (40-42), and eu-
caryotes (43-47). For example, in polymorphonuclear leu-
kocytes, calpain (a protease) is derived from its inactive
precursor by autoproteolysis (43-44). Other examples include
cathepsin D (45) and human collagenase (46). The current
observations of an FceRII-associated proteolytic activity raises
the intriguing possibility that this receptor or its 37-kD frag-
ment may be involved in the cleavage of other biologically
relevant molecules. In this regard, it is worth noting that
some differentiation antigens were recently shown to display
protease activity: examples include CD10 (or CALLA, en-
dopeptidase -24.11) (47, 48), CD13 (aminopeptidase N) (49),
and CD26 (dipeptidyl peptidase IV) (50) .
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